Dr. Del Rosso discusses treatment escalation for patients whose moderate-to-severe plaque psoriasis remains inadequately controlled with topical or conventional systemic therapies or who experience treatment-limiting
Benjamin Lockshin, MD, FAAD, the director of the Clinical Trials Center at U.S. Dermatology Partners, discusses using bimekizumab (Bimzelx) for the treatment of moderate-to-severe psoriasis
